Biological Factors in Predicting Response to Treatment in Patients With Esophageal Cancer or Rectal Cancer
Colorectal Cancer - Esophageal Cancer
Conditions: official terms
Esophageal Neoplasms
Conditions: Keywords
adenocarcinoma of the esophagus, squamous cell carcinoma of the esophagus, adenocarcinoma of the rectum, recurrent rectal cancer, stage I rectal cancer, stage II rectal cancer, stage III rectal cancer, stage IV rectal cancer, recurrent esophageal cancer, stage I esophageal cancer, stage II esophageal cancer, stage III esophageal cancer, stage IV esophageal cancer
Study Type
Study Phase
Study Design
Allocation: Non-Randomized, Primary Purpose: Diagnostic
Name: gene expression analysis Type: Genetic
Name: mutation analysis Type: Genetic
Name: polymorphism analysis Type: Genetic
Name: laboratory biomarker analysis Type: Other
Name: biopsy Type: Procedure
Name: endoscopic biopsy Type: Procedure
Overall Status
RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.

PURPOSE: This clinical trial is studying how well biological factors work in predicting response to treatment in patients with esophageal cancer or rectal cancer.
Detailed Description


- Analyze various biological factors that can be used as markers to predict response to treatment and correlate with the signaling pathway of EGFR.


- Establish a tissue bank to store information about the response to treatment and survival.

OUTLINE: Patients undergo endoscopy, 11 biopsies of tumor tissue, and 3 biopsies of healthy mucosa. Blood samples are also collected. Samples are analyzed for the expression of 4 receptors in the EGFR family, polymorphisms at intron 1 of the EGFR gene, and gene mutations in downstream signaling pathways.

After surgery, patients are followed every 3 months.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Both

- Histologically confirmed adenocarcinoma or squamous cell carcinoma of the esophagus or rectum

- Planning to receive neoadjuvant treatment, including radiotherapy or chemoradiotherapy


- Not pregnant or nursing

- No blood disorder

- Not deprived of freedom or protected by law


- See Disease Characteristics
Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle
Montpellier, France
Status: Recruiting
Contact: Marc Ychou, MD, PhD - 33-4-6761-3066 -
Start Date
November 2005
Institut du Cancer de Montpellier - Val d'Aurelle
National Cancer Institute (NCI)
Record processing date processed this data on July 28, 2015 page